- RESEARCH HIGHLIGHT
In patients with resected, high-risk melanoma, the addition of a personalized mRNA-based neoantigen therapy to adjuvant pembrolizumab was more effective than pembrolizumab alone.
By
-
Karen O’Leary
-
Karen O’Leary is an Associate Research Analysis Editor with Nature Medicine.
-
Adjuvant checkpoint inhibitor therapy is the standard of care for resectable melanoma. Although many patients derive lasting benefit from the treatment, a substantial number experience disease recurrence.
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41591-024-00006-4
Related Articles
Read more research highlights selected by the Nature Medicine team
Subjects
Latest on:
Jobs
-
Postdoctoral Fellow in Cardiac Diseases and Aging
A postdoctoral fellow position in cardiovascular diseases and cardiac aging
Rochester, Minnesota (US)
Mayo Clinic, Rochester
-
Postdoctoral Fellow – Protein Nanowire Electronics for Wearable Sensors
A postdoctoral position to develop next-generation electronic devices based on microbially produced protein nanowires.
Shenyang, China
Northeastern University
-
Faculty Positions at the Rank of Assistant Professor
Dallas, Texas (US)
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center)
-
Chief Editor, BMC Biomedical Engineering
Springer Nature is one of the leading publishers of research in the world. We publish the largest number of journals and books and are pioneers in ...
New York, NY
Springer Nature Ltd
-
Solution Specialist
Job Title: Solution Specialist Location: Beijing, China - hybrid working model About Springer Nature Springer Nature is one of the leading publis...
Beijing (CN)
Springer Nature Ltd